ISC2 Research Reveals Cybersecurity Teams Are Taking a Cautious Approach to AI Adoption
delivering insights into the early impact on team performance and hiring trends
ALEXANDRIA, Va., July 16, 2025 /CNW/ -- ISC2 – the world's leading nonprofit member organization for cybersecurity professionals – today published its 2025 AI Adoption Pulse Survey to measure the adoption of AI security tools across cybersecurity teams. Based on insights from 436 global cybersecurity professionals employed by organizations of all sizes, the research assesses the impact of AI adoption on team effectiveness, entry-level jobs and cybersecurity hiring.
"AI is reshaping how organizations operate, and cybersecurity is no exception," said ISC2 Chief Qualifications Officer Casey Marks. "Our latest AI Survey shows cautious but growing interest in AI security tools, with adoption expected to accelerate in the future. Encouragingly, 44% of professionals report no impact on hiring from current or expected adoption of AI security tools, and 28% see AI creating new opportunities for entry-level talent. Findings suggest that AI is helping cybersecurity professionals by automating repetitive tasks and enabling them to focus on more meaningful work."
Adoption of AI Security Tools
According to the AI Pulse Survey, 30% of cybersecurity professionals have already integrated AI security tools into their operations, defined in the survey as "AI-enabled security solutions, generative AI, and/or agentic AI for automatic action." Additionally, the majority (42%) are currently exploring or testing their adoption, indicating strong momentum toward future implementation. Among those who have already adopted AI security tools, 70% report positive impacts on their team's overall effectiveness.
Top five areas where AI security tools will have the most positive impact on operations in the shortest amount of time - improving efficiencies and automating time-consuming tasks:
Network monitoring and intrusion detection: 60%
Endpoint protection and response: 56%
Vulnerability management: 50%
Threat modeling: 45%
Security testing: 43%
The largest organizations, with over 10,000 employees, lead the adoption of AI tools as part of their cybersecurity operations, with 37% actively using them. This is closely followed by mid-to-large (2,500–9,999 employees) and smaller (100–499 employees) organizations, each with 33% adoption. In contrast, mid-sized (500–2,499 employees) and the smallest (1–99 employees) organizations show the lowest adoption rates, with only 20% in each group actively using AI for security. Notably, the smallest organizations are also the most conservative, with 23% reporting no plans to evaluate AI security tools.
Among industries adopting, evaluating or testing AI tools for their security operations, industrial enterprises (38%), IT services (36%), commercial/consumer sectors (36%), and professional services organizations (34%) are leading the way. In contrast, financial services and the public sector currently report the lowest adoption rates, at 21% and 16%, respectively.
However, some industries with the lowest current adoption rates are most likely to be considering AI tool integration in the future. Within both financial services and commercial/consumer sectors, 41% of professionals reported actively evaluating these tools, while 36% of those in the public sector indicated the same.
Impact on Hiring and Entry-Level Roles
A majority of respondents agree that AI security tools will affect hiring at the entry level in cybersecurity. More than half (52%) say AI will significantly or somewhat reduce the need for entry-level staff. However, 31% expressed a more optimistic view, believing that AI will also create new types of entry- and junior-level roles or increase demand, helping to counter the decline elsewhere in early-career opportunities.
Respondents expressed optimism about the wider cybersecurity hiring landscape amid AI adoption. Nearly half (44%) agreed that their organization's cybersecurity hiring has not yet been affected by the introduction of AI security tools. In contrast, 21% say AI has changed their hiring plans and priorities in their organizations.
At the same time, it's clear that AI security tools are reshaping roles and responsibilities of existing staff. According to the survey, 44% of cybersecurity professionals said that their organizations are actively reconsidering the roles and skills needed to support the adoption and use of AI security tools.
The survey report highlights key insights for organizations and hiring managers navigating the growing influence of AI in cybersecurity. As AI continues to evolve, organizations must strike a balance - embracing its efficiencies while prioritizing investment in entry-level opportunities to ensure the cybersecurity workforce remains agile, skilled and future-ready.
To explore the full survey findings including how cybersecurity professionals are adopting AI tools, and its impact on team effectiveness, entry-level roles and hiring trends, read the full report here.
About the 2025 AI Adoption Pulse Survey
ISC2 conducted an online survey to measure adoption of AI security tools across organizations, and to better understand the impact of this adoption on team effectiveness, entry-level jobs and cybersecurity hiring. In total, n=436 professionals currently working in a role with cybersecurity responsibilities participated. The survey was posted on ISC2's member dashboard pages from May 13 to May 22, 2025. For the purposes of this survey, AI security tools were defined as "AI-enabled security solutions, generative AI, and/or agentic AI for automatic action."
About ISC2
ISC2 is the world's leading member organization for cybersecurity professionals, driven by our vision of a safe and secure cyber world. Our more than 265,000 certified members, and associates, are a force for good, safeguarding the way we live. Our award-winning certifications – including cybersecurity's premier certification, the CISSP® – enable professionals to demonstrate their knowledge, skills and abilities at every stage of their careers. ISC2 strengthens the influence, diversity and vitality of the cybersecurity profession through advocacy, expertise and workforce empowerment that accelerates cyber safety and security in an interconnected world. Our charitable foundation, the Center for Cyber Safety and Education, helps create more access to cyber careers and educates those most vulnerable. Learn more, get involved or become an ISC2 Candidate to build your cyber career at ISC2.org. Connect with us on X, Facebook and LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
25 minutes ago
- Cision Canada
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR). Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter. "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients," said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. "We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs." The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA -approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success. With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide. Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible. "Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026," said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics. "Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic." The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures. "We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease," said Dr. Jacqueline Shea, President and CEO of INOVIO. "I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026." Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition. Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners. "As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders," said Howard W. Robin, President and CEO of Nektar. "Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target." The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases. CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Globe and Mail
33 minutes ago
- Globe and Mail
CDNS, NVDA Team Up to Advance Billion-Gate AI Design Power Analysis
Cadence Design Systems ( CDNS ) and NVIDIA Corporation ( NVDA ) have achieved a breakthrough with hardware-accelerated dynamic power analysis for billion-gate artificial intelligence (AI) designs, spanning billions of cycles, all completed in just a few hours with up to 97% accuracy. This advancement was made possible by combining the Cadence Palladium Z3 Enterprise Emulation Platform with the newly introduced Cadence Dynamic Power Analysis (DPA) App. For semiconductor and system developers targeting AI, machine learning (ML) and GPU-accelerated applications, this represents a major advance, enabling unmatched power profiling capabilities and significantly speeding up time to market. Today's advanced semiconductors and systems are so intricate that designers have difficulty accurately estimating their power consumption under real-world conditions. Traditional power analysis tools cannot process more than a few hundred thousand cycles without becoming impractically slow. In collaboration with NVIDIA, Cadence has overcome this challenge using hardware-assisted power acceleration and parallel processing, achieving unprecedented accuracy across billions of cycles in early design stages. The Palladium Z3 Platform's DPA App allows accurate power consumption estimates in real-world workloads, helping designers verify functionality, power and performance before tapeout—when optimizations are still feasible. This is especially beneficial for AI, ML and GPU-accelerated applications, as early power modeling enhances energy efficiency and prevents delays caused by over- or under-designed chips. Integrated with Cadence's analysis and implementation tools, Palladium DPA supports power estimation, reduction and signoff throughout the entire design cycle, aiding in the creation of the most efficient silicon and system designs. CDNS Poised for Growth on Soaring AI & Hardware Demand Broad-based demand for its solutions, especially the AI-driven portfolio, amid strong design activity, is a key catalyst. Secular trends like 5G, increasing use of hyperscale computing and autonomous driving are influencing design activity across semiconductor and systems companies. The focus on Generative AI, Agentic AI and Physical AI is leading to an exponential increase in computing demand and semiconductor innovation. This bodes well for Cadence. To capitalize on this opportunity, it has been collaborating with several tech giants, including Qualcomm and NVIDIA, on their next-generation AI designs for both training and inference. Cadence is targeting new AI markets like Life Sciences through its OpenEye drug discovery software. The company is also expanding partnerships with foundry partners such as Taiwan Semiconductor Manufacturing, Intel and Arm Holdings. Moving forward, the company is likely to benefit from customers increasing their R&D spending on AI-driven automation. On the last earnings call, Cadence highlighted that its efforts to unify EDA, IP, 3D-IC, PCB and system analysis are helping to capitalize on the opportunities presented by the AI super cycle. Additionally, customer R&D investments, especially in AI, remain strong. However, intensifying competition, headwinds pertaining to international exposure and a high level of goodwill and intangible assets are major concerns for Cadence. How CDNS' Peers are Placed in the Broader Software Space PTC Inc. ( PTC ) is a software provider offering a range of cutting-edge digital technologies that collectively revolutionize the engineering, production and maintenance of tangible goods. PTC is well-positioned to gain from its comprehensive product portfolio. The company's solutions help industrial enterprises to enhance operational efficiency, accelerate product and service innovation and boost workforce productivity. Growing clout of the company's major technology platforms, including its 3D modeling (CAD) offering Creo; lifecycle management (PLM) solution Windchill; data orchestration (IIoT) offering ThingWorx; and experience creation (AR) product Vuforia Studio, are expected to drive the top line. However, it faces stiff competition in the CAD market from Cadence Design Systems, Autodesk, ANSYS and Synopsys, to mention a few. Considering the IIoT vertical, similar solutions from large established companies like Amazon, IBM, Oracle, SAP, Siemens AG and GE are likely to affect the adoption of PTC's ThingWorx IoT platform. New entrants are likely to pressure prices or result in market share loss. San Jose, CA-based Adobe Inc. ( ADBE ) is a leading technology company offering personalized digital experiences through the infusion of AI in its solutions. Adobe continues to be the market leader in the Digital Media space. The company provides one of the best solutions in most categories of digital media design and publishing, including Internet and video. This indicates strong growth in the Creative Cloud and Document Cloud businesses. As advertising, entertainment and other content-creation markets are becoming increasingly digitalized, Adobe is well-positioned to benefit from this trend and should enjoy above-average long-term growth. Adobe entered the digital marketing space with the acquisition of Omniture. This is an area where corporate spending is on the rise. However, Adobe is facing stiff competition in the AI and GenAI space from the likes of Microsoft -backed OpenAI, as well as a lack of monetization of its AI solutions. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report Cadence Design Systems, Inc. (CDNS): Free Stock Analysis Report PTC Inc. (PTC): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Cision Canada
an hour ago
- Cision Canada
Canadian Securities Administrators release 2024-2025 Year in Review
CALGARY, AB, Aug. 14, 2025 /CNW/ - The Canadian Securities Administrators (CSA) today published its annual Year in Review, highlighting the progress made toward delivering each of the six strategic goals outlined in its 2022-2025 Business Plan. "The progress we made in the past year, as outlined in our Year in Review, is a testament to CSA members' collaboration to strengthen Canada's capital markets and introduce measures to boost competitiveness," said Stan Magidson, CSA Chair and Chair and CEO of the Alberta Securities Commission. "We've demonstrated that effective regulation can be both principled and adaptable to changing geopolitical and market conditions." The report also reflects the efforts undertaken to foster innovation in the capital markets and to protect investors. It highlights CSA members' continued efforts to disrupt and deter bad actors and hold securities law violators accountable. CSA activities noted in the report include: Issuing 1,011 investor alerts, cautions and warnings issued to help protect the public, of which more than 75 per cent related to crypto assets. Reaching over 4.5 million Canadians through our "Check Registration" and "Spot the Red Flags of Fraud" investor education campaigns. Banning permanently 54 companies and individuals from participating in the capital markets following enforcement proceedings. Taking enforcement actions in 20 crypto-related matters to protect the integrity of our capital markets. Issuing 57 publications about final adoption of rule changes, consultations, blanket orders and guidance on CSA policy developments. Hosting representatives of 155 organizations at the CSA Collaboratory's inaugural webinar on Data Portability, advancing our commitment to fostering innovation in capital markets. The CSA's 2024-2025 Year in Review is available in English and French. For more information, please see the CSA's 2025-2028 Business Plan, launched in June 2025. The CSA, the council of the securities regulators of Canada's provinces and territories, co-ordinates and harmonizes regulation for the Canadian capital markets. For investor inquiries, please contact your local securities regulator. For media inquiries, please contact: SOURCE Canadian Securities Administrators
